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Abstract
Background: The appropriateness of rheumatic mitral valve repair remains controversial due to the risks of recurrent mitral
dysfunction and need for reoperation. The aims of this study were to determine the overall short- and long-term outcomes of
pediatric rheumatic mitral valve surgery in our center.Methods: Single-center, observational, retrospective study that analyzed
the results of rheumatic mitral valve surgery in young patients, consecutively operated by the same team, between 1999 and 2014.
Results: We included 116 patients (mean age ¼ 12.6 + 3.5 years), of which 66 (57%) were females. A total of 116 primary
surgical interventions and 22 reoperations were performed. Primary valve repair was possible in 86 (74%) patients and valve
replacement occurred in 30 (26%). Sixty percent of the patients were followed up beyond three months after surgery (median
follow-up time ¼ 9.2 months [minimum ¼ 10 days; maximum ¼ 15 years]). Long-term clinical outcomes were favorable, with
most patients in New York Heart Association functional class I (89.6%) and in sinus rhythm (85%). Freedom from reoperation for
primary valve repair at six months, five years, and ten years was 96.4%+ 0.25%, 72%+ 0.72%, and 44.7%+ 1.34%, respectively.
Freedom from reoperation for primary valve replacement at six months, five years, and ten years was 100%, 91.7%+ 0.86%, and
91.7% + 0.86%, respectively. Mitral stenosis as the primary lesion dictated early reintervention. Conclusions: Despite the
greater rate of reoperation, especially when the primary lesion was mitral stenosis, rheumatic mitral valve repair provides similar
clinical outcomes as compared with replacement, with the advantage of avoiding anticoagulation.
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Introduction
Rheumatic fever is caused by group A streptococcal infections,
predominantly of the upper airway tract, secondarily inducing
immunological reactions, that affect the heart, joints, and cen-
tral nervous system. The heart valve lesions evolve over the
years to scar the valves and produce severe hemodynamic
changes, particularly in children and young adults. At least
15.6 million people are affected by rheumatic heart disease
(RHD), and annually, over 230,000 will die from the disease
around the globe.1 Rheumatic heart disease is the most com-
mon acquired heart disease in children in developing countries.
Rheumatic fever often presents with either acute or subacute
valve lesions imposing treatment. The implantation of prosthe-
tic heart valves in children is known to have major negative
impacts on their immediate and long-term survival as well as
on their quality of life and should, therefore, come only as an
alternative resource. Valve repair is the primary goal, though it
is recognized as technically challenging and more prone to
failure, as the rheumatic process is truly evolutionary, making
repair outcomes unstable.2,3
We present our single-center experience with the treatment
of rheumatic mitral valve (MV) disease in young patients,
mostly by valve repair, between 1999 and 2014. The aims of
this study were to determine the overall short- and long-term
outcomes of pediatric rheumatic MV surgery in our center and
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NYHA New York Heart Association
PISA proximal isovelocity surface area
RHD rheumatic heart disease
TEE transesophageal echocardiogram
compare the outcomes of repair versus replacement of the MV
according to the predominant lesion.
Patients and Methods
Study Design and Patient Selection
A single-center, observational, retrospective study, based on
data collection from the clinical files of consecutive patients
with rheumatic MV disease, operated over a period of 15 years,
by the same team comprising three independent surgeons.
This retrospective study was approved by the ethics com-
mittee of the hospital. All patients less than 25 years of age
were eligible for the study. Patients undergoing concomitant
surgery for aortic or tricuspid valves were not excluded.
Clinical, Echocardiographic, and Laboratory Variables
Preoperative variables included age, sex, type and severity of
mitral disease at presentation, coexisting lesions, New York
Heart Association (NYHA) functional class, rhythm status, and
C-reactive protein serum level (in mg/L). C-reactive protein
was considered elevated when 5 mg/L.
On transthoracic echocardiography, the MV area was esti-
mated using the pressure half-time method, and mitral steno-
sis (MS) was graded based on this and the mean pressure
gradient across the valve. Severe MS was defined as an
MV area < 1.0 cm2 and a mean pressure gradient across the
valve > 10 mm Hg.4
With the simplified proximal isovelocity surface area
(PISA) method, the degree of mitral regurgitation (MR) was
graded as trivial or mild (1þ): PISA radius <3 mm; moderate
(2þ): PISA radius 3 to 7 mm; and severe (3þ): PISA radius7
mm.5 Significant MR was defined as >2þ.
Operative results included primary valve repair or primary
valve replacement. Valve repair techniques included ring
implantation, chordopexy, cord replacement, commissurot-
omy, and/or leaflet extension. Early mortality was defined as
death within 30 days of surgery or in-hospital death.
Follow-up variables included follow-up time, reintervention
status, severity of residual mitral disease, NYHA functional
class, rhythm status, occurrence of embolic phenomena/major
bleeding events, and late mortality. Late mortality was defined
as death occurring after hospital discharge.
Early reoperation was defined as reoperation within the first
six postoperative months. Midterm reoperation was defined as
that occurring between the sixth postoperative month and five
years. Late reoperation was defined as that occurring between
the 5th and the 15th postoperative years.
Surgical Technique
Under general anesthesia and routine transesophageal echo-
cardiogram (TEE), patients were operated by median sternot-
omy and cardiopulmonary bypass at 32C mild hypothermia.
Dual caval cannulation with aortic return, cross-clamp, and
blood cardioplegia was standard. The MV was exposed
through a standard incision behind the interatrial groove, after
extensive (2 cm) mobilization of the right atrium to uncover
the left atrial wall. No transseptal or biatrial incisions were
made.
Carpentier’s methodology was used,6 to sequentially assess
the valve ring size and shape, its commissures, leaflets, and the
subvalvar apparatus. Different techniques were used—
extended commissurotomies, chordal mobilization, shortening
or replacement of chordae, leaflet extension, and ring implan-
tation—as appropriate. At the end of the procedure, surgical
results were assessed by saline testing, intraoperative TEE
analysis, and direct pressure measurements.
Clinical Follow-Up
Follow-up was conducted at the pediatric cardiology outpatient
clinic, with clinical and echocardiographic evaluation. Patients
were observed at regular six-month intervals. They were rou-
tinely kept under warfarin, for international normalized ratio
levels of 2.5 to 3, for a three-month period after repair, and
indefinitely for prosthetic replacements and/or the coexistence
of atrial fibrillation.
All patients were kept on secondary prophylaxis against the
recurrence of acute rheumatic fever, with a monthly intramus-
cular injection of benzathine benzylpenicillin.7 Additionally,
they were given antibiotic cover for endocarditis-prone
procedures.8
Statistical Analysis
Continuous variables were reported as means and standard
deviation, if normally distributed, or as medians and range if
not. Univariate analysis was performed using w2 or Fisher exact
test for categorical variables. Multifactorial analysis was per-
formed using logistic regression analysis and Kaplan-Meier
survival analysis. In both multifactorial tests, a dichotomized
reintervention variable was used as the dependent variable and
as the variable of interest.
In all analyses, a P value <.05 was considered statistically
significant. Statistical analysis was performed using SPSS soft-
ware (v 20.0, IBM SPSS Software for Predictive Analytics;
SPSS, Chicago, Illinois).
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Results
Population Description
We included 116 patients with a mean age of 12.6+ 3.5 years,
66 (57%) being females. A total of 138 surgical interventions
were performed on these patients between 1999 and 2014
(Table 1).
Pure MR was present in 90 (78%) patients, pure MS (12%) in
14 patients, and combined MS and MR, mixed lesions, in 12
(10%) patients. Coexisting conditions consisted of aortic invol-
vement in 65 (56%) patients, tricuspid involvement in 11 (9.5%)
patients, and atrial fibrillation in another 8 (6.9%) patients.
At presentation, 60 (52%) patients were in NYHA functional
class III and 32 (28%) patients in NYHA functional class IV. Of
the 51 patients for whom preoperative acute-phase markers were
available, C-reactive protein was found abnormally elevated in
16 (31.4%) cases, suggesting the presence of rheumatic inflam-
mation activity at the time of surgery. Although surgical inter-
vention was normally postponed in the presence of acute disease,
in some cases (16 patients), it was prompted by the severity of
clinical manifestations and hemodynamic instability.
Surgical Technique
Mitral disease prompted surgical treatment in the majority
of patients (96.5%); in four cases, aortic valve disease
predominated, the MV being approached in the context of aor-
tic valve surgery (Tables 1 and 2).
Primary valve repair was possible in 86 (74%) patients. In
68 (79%) of the MV repair patients, a semirigid Carpentier’s
prosthetic ring was applied (sizes # 26-34) as part of the repair,
complementing other standardized techniques. Chordopexy or
cord replacement was common, having been applied to 54
(63%) of the patients.
Valve replacement was the primary surgical option in 30
(26%) patients. In this group, prosthetic valves sizes #18 to
29 were implanted.
Table 1. Characteristics of the Young Patients Undergoing MV Surgery.
Age at surgery, mean + SD, years 12.6+ 3.5
1-5 years 1 (0.9%)
6-10 years 24 (20.7%)
11-15 years 61 (52.6%)
16-20 years 28 (24.1%)
21-25 years 2 (1.7%)
Male, n (%) 50 (34)
Female, n (%) 66 (57)
Mixed Lesions (n ¼12)
Pure MR (n ¼ 90) Pure MS (n ¼ 14) MR MS Total (N ¼ 116)
Severity at presentation, n (%)
Mild 1 (1.1) – 1 (8.3) 2 (16.7)
Moderate 8 (8.9) – 3 (25) 3 (25)
Severe 81 (90) 14 (100) 8 (66.7) 7 (58.3)
Coexisting lesions, n (%)
Aortic 55 (61.1) 5 (35.7) 5 (41.7) 65 (56)
Tricuspid 7 (7.8) 2 (14.3) 2 (16.7) 11 (9.5)
NYHA functional class, n (%)
I 4 (4.4) 1 (7.1) – 5 (4)
II 17 (18.9) 2 (14.3) – 19 (16)
III 45 (50) 7 (50) 8 (66.7) 60 (52)
IV 24 (26.7) 4 (28.6) 4 (33.3) 32 (28)
Sinus rhythm, n (%) 85 (94.4) 11 (78.6) 9 (75) 105 (90.5)
Other rhythm, n (%) 5 (5.6) 3 (21.4) 3 (25) 11 (9.5)
C-reactive protein, n (%)
<5 mg/L 25 2 8 35 (68.6)
5 mg/L 11 5 – 16 (31.4)
Abbreviations: MR, mitral valve regurgitation; MS, mitral valve stenosis; MV, mitral valve; NYHA, New York Heart Association.







(n ¼ 12) Overall
Primary valve repair, n (%) 73 (81.1) 8 (57.1) 5 (41.7) 86 (74)
Carpentier ring, n 63 1 4 68
Chordopexy/cord
replacement, n
52 2 – 54
Commissurotomy, n 69 7 3 79
Leaflet extension, n 48 – – 48
Primary valve replacement,
n (%)
17 (18.9) 6 (42.9) 7 (58.3) 30 (26)
Abbreviations: MR, mitral valve regurgitation; MS, mitral valve stenosis.
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Early Surgical Outcomes
No operative mortality was registered. Overall, 20 (17%)
patients experienced early surgical complications: rhythm
disturbances (n ¼ 9), ventricular dysfunction (n ¼ 5), hemo-
dynamically significant pericardial effusion (n ¼ 3),
pneumothorax (n ¼ 2), and catheter-associated septicemia
(n¼ 1). There was no significant association between the type
of surgery performed and the occurrence of early complica-
tions (P ¼ .89).
Late Outcomes
Sixty percent of the patients were followed up beyond three
months after surgery. Median follow-up time was 9.2 months
(minimum [min] ¼ 10 days; maximum [max] ¼ 15 years;
Table 3).
The wide range in follow-up times is due to the high
proportion of African patients who returned to their coun-
tries of origin as soon as their clinical status allowed for
transfer. In our analysis, once these patients return to their
countries of origin, they are considered lost to follow-up
and censored.
At the time of the latest outpatient clinic visit, most
(89.6%) of the patients were in NYHA functional class I,
the vast majority (93%) showing clinical improvement from
presentation. There were no patients in functional class III
or IV.
Of the 58 (50%) patients with residual MR, only one had
severe (>2þ) regurgitation. Twenty-three (20%) patients pre-
sented with residual MS, all with mild to moderate disease.
Most (85%) of the patients had normal sinus rhythm. Five
(4.3%) patients experienced thromboembolic phenomena:
three prosthetic valve thrombosis and two nonlethal cerebral
thromboembolisms. Both patients with cerebral thromboembo-
lism had atrial fibrillation. There were no documented major
bleeding events or late mortality.
Reintervention
Twenty (17%) patients were submitted to a total of 22 reopera-
tions, in a median 22.7 months after primary surgery (min: 14
days; max: 8.5 years). The primary valve surgery was valve
repair in 19 of the patients and valve replacement in 3 (Table 4).
Reoperations were predominantly performed for MV
dysfunction.
During reoperation, MV replacement was performed in 20
(91%) patients and a second MV repair done in 2 (9%). Inter-
estingly, reoperation was found to have a bimodal peak: ini-
tially around 16 weeks postoperatively and midterm (Figure 1).
There were 6 (27.4%) early, 13 (59%) midterm, and 3 (13.6%)
late reoperations.
A log-rank test was run to determine whether there were
differences in the time elapsed until reintervention for the
three types of MV disease: MR, MS, and mixed lesions. Rein-
tervention was significantly earlier for MS (median time to
reintervention ¼ 42 months) as compared to MR (median
time to reintervention ¼ 107 months), P ¼ .012. There were
no statistically significant differences between the two types
Table 3. Follow-Up Characteristics of the Young Patients After MV
Surgery.
NYHA functional class, n (%)
I 104 (89.6)
II 7 (6)
Missing information 5 (4.4)
Sinus rhythm, n (%) 99 (85)
Embolic phenomena, n (%) 5 (4.3)










Abbreviations: MV, mitral valve; NYHA, New York Heart Association.
Table 4. Reintervention Rate per Characteristics.




Type of primary surgery




(1)a 12 0.59 (0.22-1.60)b .293
(2)a 5 1.44 (0.47-4.49) b .543
(3)a 3 1.71 (0.42-6.96)b .432
Abbreviations: CI, confidence interval; OR, odds ratio.
aEach number represents a different surgeon.













Figure 1. Hazard function for reintervention (time in years).
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of lesions mentioned above and the mixed lesions (median
time to reintervention ¼ 98 months), P ¼ .05 (Figure 2).
For MR, freedom from reoperation at six months and five
years was 96.6%+ 0.20% and 84.4%+ 1.09%, respectively.
For MS, freedom from reoperation at six months and five years
was 79.6%+ 0.66% and 22.6%+ 1.97%, respectively. Free-
dom from reoperation by grade of residual mitral stenosis and
regurgitation is shown in Figures 4 and 5, respectively.
The only significant association to predict reintervention
was the type of the primary surgical option, with primary valve
repair having an odds ratio of 8.22 (95% confidence interval:
1.05-64.4) for reintervention when compared to primary valve
replacement (P ¼ .023).
Both the preoperative elevated C-reactive protein and the
surgeon performing the primary procedure showed no signifi-
cant association with the rate of reintervention, even when
adjusted for the type of primary procedure in the multivariate
analysis (Table 4).
Median time to reintervention after primary valve replace-
ment was 90 months, whereas median time to reintervention
after primary valve repair was 108 months (Figure 3).
Freedom from reoperation for primary valve repair at six
months, five years, and ten years was 96.4%+ 0.25%, 72%+
0.72%, and 44.7%+ 1.34%, respectively. Freedom from reo-
peration for primary valve replacement at six months,
five years, and ten years was 100%, 91.7% + 0.86%, and
91.7% + 0.86%, respectively.
Comment
Valve lesions due to RHD are common, mostly in patients
coming from developing countries, and its prevalence is gain-
ing more relevance with recent migrations. The treatment for
these patients represents both a medical and surgical challenge
and also a burden. Being an old lesion, recent papers in the
literature2,3 are bringing this subject to present attention, mean-
ing that this is an unresolved issue for medicine.
In this article, we described our results for a young RHD
patient population consecutively treated over 15 years, with a
primary intention to repair their MVs. We described in the
series what concerns patients’ preoperative differential charac-
teristics, surgical repair techniques used, and achieved out-
comes, both early and late.
Transformation of the acute inflammatory process into
fibrosis, over time, is the main pathological mechanism respon-
sible for impairing valve function, MV being the one most
frequently affected in rheumatic carditis. Valvular fibrosis can
be exacerbated by recurrent rheumatic fever episodes and can
affect both the valvar leaflets and the subvalvular apparatus by
increasing tissue thickness, gradual scaring, and retraction,
leading to deformation and subsequent calcification over time.
In acutely presenting patients, the primary lesion is normally
annular dilatation (Carpentier type I lesion)6 and frequently
anterior leaflet prolapse, due to inflammatory chord elongation
(Carpentier type IIa lesion).6 Some of these patients will addi-
tionally have myocardial ventricular dysfunction due to inflam-
matory pancarditis.
In patients presenting with already established lesions, MR
was present in 90 (77.6%), MS in 14 (12.1%), and mixed
lesions in another 12 (13.4%) patients.
We will discuss the techniques used to treat each anatomical
form and their impacts on long-term outcomes. Typically,
established lesions causing MR consist of coexisting Carpen-
tier type II (involving A2 segment) and type IIIa (involving the
posterior leaflet, invariably retracted by scaring), whereas
lesions causing MS consist of commissural fusion, not rarely
extending to chordae and papillary muscles, all involved in the
fibrotic process, representing Carpentier type III lesions.6
























Figure 2. Kaplan-Meier survival function for reintervention by type of






















Figure 3. Kaplan-Meier survival function for reintervention by type of
surgery (time in years).
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circular, and this type I lesion impairs leaflet coaptation and
worsens MV regurgitation.
In our series, individualized surgical techniques were used
to address every lesion oriented by TEE at the time of surgery.
Annulus dilatation and deformity were always treated by
prosthetic ring implantation, in order to correct the native
mitral annulus remodeling and to improve long-term durability
of the repair. The major disadvantage of ring implantation is
that sizes below 26 are potentially restrictive in a growing child
and more so in the face of MS as the presenting dominant
lesion.
Nevertheless, ring implantation seems mandatory, as failure
to perform annuloplasty at the time of the initial valve repair
has been reported as a predictive factor of early reoperation9,10;
this is also confirmed by our earlier personal experience. Some
authors claim that the implantation of pediatric biodegradable
rings will achieve superior results, not only at the valve level
but also by better preserving ventricular geometry and func-
tion11 (Table 5).
Over the years, we have opted to compromise with the
implantation of semirigid rings (as flexible rings do not seem
to allow for stable repairs in patients with RHD) and by using
as large as possible rings, its size guided mainly by the inter-
trigone distance and the area of the anterior leaflet (although
these measurements might be affected by the rheumatic scaring
process itself).
In a previous study from our group,12 we have demon-
strated that the correlation between patient body surface
area and MV ring size is by no means perfect in this grow-
ing rheumatic population. In fact, we were able to demon-
strate that whenever pericardial extension was used to
correct posterior leaflet retraction, a bigger size ring could
be implanted, reducing the likelihood of early restenosis.
Ring size did correlate significantly with the use of poster-
ior leaflet extension.
Table 5. Main Features of Other Studies on RHD Mitral Valve Repair in Children.18,19,20,21







1 n ¼ 22 (19 MV
repair/3 MV
replacement)
14.3+ 3.8 years Rumel debridement; prosthetic ring annuloplasty; partial
posterior annuloplasty; commissurotomy; commissuroplasty
0% 2 (7.7%) 5 (23%)
2 n ¼ 278 11.7+ 2.9 years Posterior collar annuloplasty; commissurotomy, cusp-level
chordal shortening, cusp thinning, cleft suture, and cusp
excision or plication
6 (2.2%) 7 (2.6%) 16 (6%)
3 n ¼ 220 11.8+ 3.0 years Commissurotomy, chordal shortening, cusp thinning, chordal
transfer, secondary or primary posterior chordal resection,
and posterior leaflet suspension. 97% annuloplasty rings; 81%
rigid Carpentier-Edwards ring; 19% biodegradable Kalangos
ring
0% 1 (0.5%) 12 (5.5%)
4 n ¼ 36 11.3+ 3.9 years Leaflet suspension to the contralateral annulus 0% 0% 3 (8.3%)

















Figure 4. Kaplan-Meier survival function for reintervention by grade

















Figure 5. Kaplan-Meier survival function for reintervention by grade
of residual mitral regurgitation (time in years).
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Also, extending the posterior leaflet, ideally with autologous
prefixed pericardium, as well as sectioning secondary chordae,
commonly fused, improves leaflet coaptation. In this cohort,
posterior leaflet extension and secondary chord sectioning were
done in 67% of the cases (please note that MR was present in
77.6% of the population, therefore, pericardial extension was
indeed a common procedure).
On the anterior leaflet, extension is almost never needed,
but all efforts must concentrate on correcting any existing
leaflet prolapse due to chordal elongation, and this is usual for
the A2 segment.
Prolapse of the anterior leaflet, caused by chord elongation
or, more rarely, rupture, commonly affecting A2 segment can
be corrected by chord shortening, chord transfer, or artificial
chord implantation. Chord shortening and transfer techniques
were chosen according to the degree of thickness and retraction
of primary anterior chordae tendineae (63% in this cohort). In
the active carditis, we tried, whenever possible, to avoid both
chord shortening and transfer techniques because of the tissue
fragility induced by the inflammatory process. In such cases,
the use of artificial chords reinforced with small pericardial
pledgets at both implantation sites can potentially decrease the
rate of early repair failure.13
Restricted motion of the anterior and/or posterior leaflets
due to commissural fusion can be treated by commissurotomy
(92% in this cohort), usually extending to, and splitting the
papillary muscles and also by resection/mobilization of the
secondary posterior chordae, by direct leaflet thinning, and
by leaflet enlargement using autologous pericardium.
In 30 (26%) patients, the extension of the scaring process
and/or the presence of calcifications dictated primary valve
replacement by a mechanical prosthesis, the native valve being
deemed as not repairable.
We had a low percentage of short-term complications (17%)
that favorably compare to those described in the literature.10,14–16
Furthermore, no early surgical mortality was documented.
Clinical long-term outcomes until 15 years of follow-up
were also favorable, with most (89.6%) patients in NYHA
functional class I and the majority (85%) in sinus rhythm. At
the time of the latest evaluation, 81 (69.8%) patients presented
with some kind of residual lesion, 73% being classified as mild
and only 1.2% as severe. Five (4.3%) patients experienced
thromboembolic phenomena. Notably, three of these patients
had a prosthetic valve thrombosis related to anticoagulation
therapy noncompliance.
Interestingly, reoperation, whenever needed, was found to have
a bimodal peak distribution, initially around 16 weeks postopera-
tively and midterm (six months to five years postoperatively).
The early peak in the instantaneous hazard might be attrib-
uted to suboptimal repair or inherent extreme complexity of the
disease process. Residual MR > 1þ and lack of concomitant
ring annuloplasty have been identified in the literature as pre-
dictors of repair failure.10,13,17 Moreover, Yakub and col-
leagues demonstrated that rheumatic MV repair at a younger
age (<20 years) was an independent predictor of reoperation
and valve failure.2
In this cohort, MS as the primary lesion has dictated the
need for early reintervention, with a median time to reinterven-
tion of 42 months, as compared to MR, with a median time to
reintervention of 107 months, P ¼ .012. Mitral stenosis is
widely recognized as a risk factor for reoperation.
It has been recognized that acute inflammation does predict
a poorer outcome.13 In the study population, however, elevated
preoperative C-reactive protein levels did not correlate with the
reoperation rate, probably due to the small number of patients
in these conditions (16 patients). However, it seems wise to
stabilize patients preoperatively with anti-inflammatory agents
and to defer surgery until their rheumatic activity lowers.
In our population, midterm failures have been attributed to
recurrence and/or progression of the inflammatory rheumatic
process. It is our belief that continuing disease process and/or
recurrent disease is the main cause of late valve failure at
younger ages. That is why we have kept all our patients post-
operatively on penicillin prophylaxis.
In our series, freedom from reoperation for primary valve
repair at six months, five years, and ten years was 96.4% +
0.25%, 72% + 0.72%, and 44.7% + 1.34%, respectively.
Freedom from reoperation for primary valve replacement at
six months, five years, and ten years was 100%, 91.7% +
0.86, and 91.7% + 0.86, respectively.
Although a higher reoperation rate for MV repair was
expected and extensively described in the literature, the differ-
ence in freedom from reoperation for the two procedures—valve
repair or replacement—lies in the great disparity of patients
submitted to primary repair (74%) versus replacement (26%).
Indeed, in a review of a 40-year experience with pediatric
MV replacement in an heterogeneous group of 97 patients
with congenital and acquired mitral disease, Brown and col-
leagues found high rates (35%) of reoperation (freedom from
reoperation at 10 years¼ 71% and at 20 years¼ 63%). Also, very
high levels of valve-related complications and latemortality have
occurred in their series. They concluded that MV replacement
should be reserved only for medical and repair failures.15
In conclusion, despite the greater rate of reoperation, rheu-
matic MV repair provides noninferior clinical outcomes, as com-
pared to MV replacement. However, it has the advantage of
being associated with fewer thromboembolic events, particularly
in a pediatric population, fairly noncompliant to anticoagulation,
and more so in developing countries, where access to hypocoa-
gulation control is limited. In addition to this, somatic growth
and pregnancy remain important issues in young patients.2
Therefore, although patients with RHD present special
challenges, MV repair should be preferred over prosthetic
replacement, whenever technically possible. In our center, the
overall short- and long-term outcomes of pediatric rheumatic
MV repair are good and compare most favorably with those
described in the literature.
Study limitations
This study is based on a single-center series that is susceptible
to referral bias and institution-specific practices. The
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nonrandomized design may have affected the results due to the
presence of unmeasured confounders, procedure bias, or detec-
tion bias, despite the use of statistical adjustments. The varia-
tions in results depend on the attending surgeon’s discretion
regarding different techniques and the level of acceptance of
their repair results.
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